© 2021 MJH Life Sciences and Center for Biosimilars®. All rights reserved.
© 2021 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
February 6th 2021
By Deana Ferreri, PhD
A long-term observational study suggests a non-medical switch from infliximab to SB2 is “a feasible option” for patients with inflammatory bowel diseases (IBD).
January 19th 2021
By Tony Hagen
The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.
January 18th 2021
Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.
January 14th 2021
A need for clinical evidence on the efficacy and safety of infliximab switching led the authors to pursue this investigation.
December 27th 2020
In part 2 of this year-end feature, we look at the most-read biosimilar stories of the second half of 2020.
December 24th 2020
The top stories in biosimilars for 2020 encompassed biosimilar approvals and launches, the coronavirus disease 2019 pandemic, and the FDA's challenge to stay on top of the rapidly changing health care landscape.
December 19th 2020
In the EU-5 group of countries, biosimilar awareness is poor, hindering uptake of these potentially cost-saving medicines, a white paper states.
December 16th 2020
Samsung Bioepis hopes to gain regulatory approval for a denosumab biosimilar referencing Prolia. The trial will focus on women with postmenopausal osteoporosis.
December 10th 2020
Two studies of trastuzumab biosimilars have improved understanding of these medicines as monotherapy and in combination with other agents in metastatic breast cancer.
December 8th 2020
A high overall response rate of 93% was observed for patients with immune thrombocytopenic purpura who received romiplostim biosimilar.